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Abstract
Background: The VEGF-independent angiogenic signaling plays an important role in the development of colorectal cancer
(CRC). However, its implication in the clinical outcome of CRC has not been reported. This study aimed to investigate the
association between genetic variations in several major VEGF-independent signaling pathway genes and the overall survival
of CRC patients.
Methods: Seven single nucleotide polymorphisms (SNPs) in four important VEGF-independent angiogenic genes (ANGPT1,
AMOT, DLL4 and ENG) were genotyped in a Chinese population with 408 CRC patients.
Results: One SNP, rs1954727 in ANGPT1, was significantly associated with CRC overall survival. Compared to patients with
the homozygous wild-type genotype of rs1954727, those with heterozygous and homozygous variant genotypes exhibited
a favorable overall survival with a hazard ratio (HR) of 0.89 (95% confidence interval [CI] 0.55–1.43, P=0.623), and 0.32 (95%
CI 0.15–0.71, P=0.005), respectively (P trend=0.008). In stratified analysis, this association remained significant in patients
receiving chemotherapy (P trend=0.012), but not in those without chemotherapy. We further evaluated the effects of
chemotherapy on CRC survival that was stratified by rs1954727 genotypes. We found that chemotherapy resulted in a
significantly better overall survival in the CRC patients (HR=0.44, 95% CI 0.26–0.75, P=0.002), which was especially
prominent in those patients with the heterozygous genotype of rs1954727 (HR=0.45, 95%CI 0.22–0.92, P=0.028).
Conclusion: Our data suggest that rs1954727 in ANGPT1 gene might be a prognostic biomarker for the overall survival of
CRC patients, especially in those receiving chemotherapy, a finding that warrants validation in larger independent
populations.
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Introduction
Worldwide, colorectal cancer (CRC) is the third most common
malignancy and the fourth leading cause of cancer death with an
estimated 1,234,000 new cases and 608,000 deaths in 2008 [1].
CRC is a disease that is largely influenced by lifestyle and dietary
factors [2], however, recent studies have suggested that inter-
individual genetic variations may significantly affect the risk of
CRC [3,4,5]. In addition, accumulating evidence, including those
from our own studies, has also shown that single nucleotide
polymorphisms (SNPs) may be used as surrogate biomarkers of the
genetic background of CRC patients to predict therapeutic
response and prognosis [6,7,8,9].
Tumor angiogenesis, the generation of new blood vessels, is a
crucial cellular process that influences tumor cell growth, invasion,
local-regional recurrence, and metastatic spread of CRC, making
it an attractive target for anticancer drug development [10].The
tumor cell growth, invasion, and metastases are heavily influenced
by the balance of functions of endogenous angiogenic and anti-
angiogenic factors [10]. The vascular endothelial growth factors
(VEGFs) and its receptors (VEGFRs) play a central role in the
angiogenesis pathway [11]. The functional inhibitors of VEGF
and VEGFRs, such as anti-VEGF neutralizing antibody and small
molecules that block the tyrosine kinase activity of VEGFRs, have
been approved as anti-angiogenesis therapies for many cancers,
including CRC [12]. However, the wide resistance to the anti-
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search for treatments targeting the VEGF-independent angiogen-
esis pathway [12,13], such as pro-angiogenic pathways mediated
by angiopoietins/TIE-2 and Delta/Notch [14,15], as well as anti-
angiogenic pathways mediated by angiomotin and endoglin
proteins [16,17].
Genetic variations in the VEGF gene have been reported to
modulate VEGF gene expression [18,19,20]. They have also been
associated with the etiology and clinical outcomes of CRC
[21,22,23]. However, although basic studies have revealed an
essential role of VEGF-independent pathway genes in the etiology
and clinical outcome of CRC, no study has been reported on the
association between the genetic variations of these genes and CRC
prognosis. The aim of the current pilot study was to evaluate the
association between SNPs in several major VEGF-independent
angiogenic pathway genes with the overall survival of CRC
patients.
Materials and Methods
Ethics
This study was approved by the institutional review boards of
the Fourth Military Medical University. A written informed
consent with a signature was obtained for each patient.
Patient population and clinical data collection
This study was focused on the VEGF-independent angiogenesis
gene SNPs as potential predictors of CRC prognosis. Therefore,
all subjects included in this study had histopathologically
confirmed CRC. Originally, 496 CRC patients were recruited
between February 2006 and April 2010 from the Departments of
General Surgery in the Xijing Hospital and the Tangdu Hospital
that are affiliated with the Fourth Military Medical University in
Xi’an, China. There were no recruitment restrictions on age,
gender, and cancer stage. All CRC patients had no previous
history of other cancers, chemotherapy, or radiotherapy. All CRC
patients were newly diagnosed and histopathologically confirmed
as having adenocarcinoma. For the purposes of this study, 88
patients were excluded, for the following reasons: did not undergo
surgery or only received palliative operation (26 patients), had
incomplete clinical information or lacked follow-up (48 patients),
died within one month of surgery (6 patients) and had poor quality
and/or quantity of DNA sample (8 patients). Finally, 408
surgically resected patients with complete clinical and follow up
data as well as high quality DNA samples were included in the
present study. All patients were Han Chinese.
Demographic and clinical data
Detailed demographic and clinical information was collected
through in-person interview, medical chart review, or consultation
with treating physicians. The demographic data collected include
age, gender, ethnicity, smoking status, drinking status, and body
mass index (BMI). The clinical data collected include time of
diagnosis, time of surgery and/or chemotherapies, time of death,
tumor stage, differentiation, location site, lymph node invasiveness,
treatment protocol, and serum CEA (carcinoembryonic antigen).
A standard follow-up was performed by a trained clinical specialist
through on-site interview, direct calling, or medical chart review.
The latest follow-up data in this analysis was obtained in February
2011. For patient enrolled after August 2008, 5-ml of blood was
available for genomic DNA extraction using the E.Z.N.A. Blood
DNA Midi Kit (Omega Bio-Tek, Norcross, GA). For patients
enrolled before August 2008, genomic DNA was extracted from
approximately 100 mg of adjacent normal tissues obtained by a
pathologist after surgery using the E.Z.N.A. tissue DNA Kit
(Omega Bio-Tek).
SNP selection and genotyping
Four major genes in the VEGF-independent angiogenic
pathway were studied, including AGNPT1 which encodes a TIE2
agonist that stimulates the PI3K-Akt signaling pathway as a
survival signal and stabilizes blood vessels, DLL4 (Delta-like 4
ligand), which encodes a protein that is secreted from endothelial
cells and promotes angiogenesis by suppressing non-functional
sprouting of vascular endothelial cells, AMOT (Angiomotin) which
encodes an angiostatin inhibitor that mediates tube formation and
migration of endothelial cells toward growth factors during the
formation of new blood vessels, and ENG (Endoglin) which
encodes a component of the transforming growth factor beta
receptor complex involved in angiogenesis, cardiovascular devel-
opment, and vascular homeostasis. Potentially functional SNPs, in
functional regions including promoters, exons, and untranslated
regions (UTRs) were selected using a set of web-based SNP
selection tools (freely available at http://snpinfo.niehs.nih.gov/
snpfunc.htm), by which one can select SNPs based on linkage
disequilibrium (LD) and predicted functional characteristics of
both coding and non-coding SNPs. The 59 and 39 flanking regions
were arbitrarily set at 1000 bp for all genes. Only validated SNPs
were selected and SNPs with minor allele frequency (MAF) ,5%
in Asian population were excluded. In the case of multiple
potentially functional SNPs within the same haplotype block
(defined by the linkage coefficient r
2.0.8), only one SNP was
included. Finally, a total of seven SNPs were identified for the four
genes, including two SNPs in ANGPT1 (rs1954727 and
rs9297395), three SNPs in AMOT (rs2286064, rs2286063,
rs640009), one SNP in DLL4 (rs12439845) and one SNP in ENG
(rs7865146). Genotyping was performed using the Sequenom
iPLEX genotyping system (Sequenom Inc, CA). Laboratory
personnel conducting genotyping were blinded to patients’
information. The average call rate for the genotyping was
99.4%. Strict quality control measures were implemented during
genotyping with over 99% concordance between samples
genotyped in duplicate.
Statistical analysis
The endpoint evaluated in this study was overall survival,
defined as the time from initial surgery to death or last follow-up.
Hazard ratio (HR) and 95% confidence interval (95% CI) were
estimated using a multivariate Cox proportional hazards model,
adjusting for age, gender, smoking status, drinking status, BMI,
tumor position, tumor differentiation, tumor stage, and chemo-
therapy, where appropriate. Haplotype/diplotype was determined
using the HelixTree software (Golden Helix, Inc.), and HR was
estimated by multivariate Cox proportional hazards model, using
the haplotype/diplotype containing all wild-type alleles as
reference. The tests for interactions between SNPs and DNA
source were conducted by including a cross-product term into the
Cox proportional hazards model. Log-rank test was used to assess
the differences of overall survival between different patient groups.
SAS statistical package (SAS software version 9.2, Cary, NC) was
used for the analyses. All P values in this study were two-sided.
P#0.05 was considered the threshold of statistical significance.
Results
Patients Characteristics
A total of 408 surgically resected CRC patients were included in
this study, with an average age of 59.4 years (range, 22 to 90 years)
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56.4% (n=230) were males and 46.6% (n=178) were females.
The majority of patients were never smokers (70.8%) and never
drinkers (89.5%). The percentage of the patients with colon cancer
(47.1%) was slightly lower than rectum cancer patients (52.9%).
About 47.1% of patients had stage II tumor, whereas stage 0, I, III
and IV tumors were present in 2.0%, 14.2%, 27.2% and 9.6% of
patients, respectively. Approximately 66.4% of patients had
moderately differentiated tumors and 78.2% patients were treated
with chemotherapy after surgery. In a median follow-up time of
22.9 months, approximately 23.0% (n=94) of the patients were
deceased as of the last follow up (February 2011) (Table 1).
Association between individual SNPs and overall survival
in CRC patients
The associations of the seven selected SNPs with CRC survival
were analyzed using univariate and multivariate analyses adjusting
for age, gender, smoking status, drinking status, BMI, tumor
position, tumor differentiation, tumor stage, and chemotherapy.
The results were summarized in Table 2. Among them, one SNP,
rs1954727 located in the 39 UTR region of the ANGPT1 gene, was
significantly associated with the overall survival in CRC patients in
both univariate and multivariate analyses. In multivariate analysis,
compared to the homozygous wild-type genotype (WW), the
heterozygous (WV) and homozygous variant genotype (VV) of
rs1954727 was associated with an HR of 0.89 (95% CI 0.55–1.43,
P=0.623) and 0.32 (95% CI 0.15–0.71, P=0.005), respectively,
with a significant dose-response effect observed (P trend=0.008,
Table 2). Log rank test indicated a significant difference in overall
survival between the wild-type and homozygous variant genotypes
of rs1954727 (Log rank P=0.019, Figure 1). These results
indicated that rs1954727 was an independent predictor of CRC
survival in our study population. In addition, we randomly
selected 50 patients included in this study with both blood and
normal tissues available and genotyped all the seven SNPs in both
blood and tissue DNAs for these patients. The genotyping results
were 100% concordant between blood and tissue DNA samples.
Furthermore, for each of the seven SNPs, we conducted a test for
interaction (heterogeneity) between the SNP and DNA source and
did not identify any significant interaction (P for interaction for
overall survival ranges from 0.143 for rs1954727 to 0.651 for
rs2286063, data not shown). Taken together, these lines of
evidence indicated that the different DNA sources did not affect
the findings identified in this study.
Association of rs1954727 with overall survival of CRC
patients stratified by host characteristics
We further analyzed the effect of rs1954727 on overall survival
in CRC patients stratified by demographic and clinical charac-
teristics. As shown in Table S1, the significant better overall
survival conferred by rs1954727 was observed in older patients
(HR=0.12, 95% CI, 0.03–0.60, P=0.010), male patients
(HR=0.20, 95% CI, 0.05–0.75, P=0.017), never smokers
(HR=0.28, 95% CI, 0.11–0.73, P=0.009), never drinkers
(HR=0.35, 95% CI, 0.15–0.84, P=0.018), and the patients with
lower education level (HR=0.28, 95% CI, 0.08–0.94, P=0.040),
with chemotherapy (HR=0.33, 95% CI, 0.14–0.79, P=0.012),
with colon cancer (HR=0.09, 95% CI, 0.02–0.40, P=0.002),
with poor and moderate tumor differentiation (HR=0.32, 95%
CI, 0.13–0.78, P=0.012), with stage 3 or 4 tumors (HR=0.16,
95% CI, 0.04–0.65, P=0.011), and with both lower or higher
BMI (HR=0.20, 95% CI, 0.04–0.97, P=0.045, or HR=0.32,
95% CI, 0.11–0.92, P=0.035, respectively). The significant dose-
dependent effect conferred by rs1954727 was evident in patients
who were older (Ptrend=0.006), male (Ptrend=0.012), never smoker
(Ptrend=0.021), never drinker (Ptrend=0.025), and patients with
higher BMI (Ptrend=0.025), with chemotherapy (Ptrend=0.012),
with tumor position of colon cancer (Ptrend=0.012), with poor and
moderate tumor differentiation (Ptrend=0.016), and with advanced
tumor stage of 3–4 (Ptrend=0.003). Among the 319 patients
receiving chemotherapy, 308 (96.6%) received the FOLFOX
regimen, including folinic acid (FOL), fluorouracil (F) and
Oxaliplatin (OX). Restricting the analysis to those patients
receiving the FOLFOX yielded similar results to those of the
current analysis (data not shown).
Modulating effects of chemotherapy on CRC overall
survival by rs1954727
Because the majority of CRC patients in this study were treated
with chemotherapy, we further assessed the modulating effects on
the association between chemotherapy and overall patient
survival, stratified by rs1954727. As shown in Table 3, patients
receiving chemotherapy had a significantly better overall survival
Table 1. Demographic and clinicopathological characteristics
of patients with CRC.
Variables Number of patients (%), N=408
Age, average(range) (in years) 59.4 (22–90)
Body mass index, mean (range) 22.7(15.8–32.9)
Gender
Male 230 (56.4)
Female 178(46.6)
Smoking status
Ever 119 (29.2)
Never 289 (70.8)
Drinking status
Ever 43 (10.5)
Never 365 (89.5)
Tumor position
Colon 192 (47.1)
Rectum 216 (52.9)
Tumor stage
0 8 (2.0)
I 58 (14.2)
II 192 (47.1)
III 111 (27.2)
IV 39 (9.6)
Tumor differentiation
Poor 37 (9.1)
Moderate 271 (66.4)
Well 100 (24.5)
Chemotherapy
Yes 319 (78.2)
No 89 (21.8)
Death
Yes 94 (23.0)
No 314 (77.0)
doi:10.1371/journal.pone.0034758.t001
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patients without chemotherapy. This significant effect on patient
survival conferred by chemotherapy was only observed in patients
with the heterozygous genotype of rs1954727 in the stratified
analysis (HR=0.45, 95% CI 0.22–0.92, P=0.028), but not in
those carrying the homozygous wild-type or variant genotype.
Haplotype and diplotype of ANGPT1 gene and CRC
overall survival
The haplotype and diplotype analyses were conducted to
evaluate the combined effect of the two SNPs in the ANGPT1 gene
on CRC overall survival. As shown in Table 4, there were four
haplotypes in the order of rs9297395 and rs1954727 (W_W:
52.5%, W_V: 42.2%, V_W: 4.3%, and V_V: 1.0%) and three
diplotypes (W_W-W_W: 28.8%, W_W-W_V: 44.3%, and W_V-
W_V: 19.7%) with a frequency .1% in the study population.
When compared with the haplotype containing the wild-type allele
for the two SNPs (W_W), patients with the haplotype of W_V
exhibited a significantly better overall survival (HR=0.59, 95%CI
0.42–0.83, P=0.002), which was consistent with the main effect
analysis of the rs1954727 SNP. For diplotype analysis, when
compared with the diplotype containing the homozygous wild-
type genotype for both SNPs (W_W-W_W), diplotype containing
one copy of the W_V haplotype (W_W-W_V) and two copies of
W_V haplotype (W_V-W_V) exhibited a progressively improved
overall survival with an HR of 0.74 (95% CI 0.44–1.24, P=0.247)
and 0.30 (95% CI 0.13–0.67, P=0.004), respectively. We also
performed the haplotype and diplotype analyses for the three
SNPs in AMOT gene, however, no significant findings were
observed (data not shown).
Discussion
In this study, we reported a significant association of the overall
survival in a cohort of 408 surgically-treated CRC patients with a
genetic variant, rs1954727, in ANGPT1, a pivotal gene in the
VEGF-independent angiogenic signaling pathway. Furthermore,
we identified a plausible interaction between this SNP and
chemotherapy on modulating CRC patient survival.
Angiogenesis inhibitors targeting the VEGF signaling pathway,
such as bevacizumab, sunitinib, and sorafenib, have demonstrated
significant therapeutic efficacy in various cancers and been
Table 2. Association of SNPs with overall survival in CRC patients.
Gene Region SNP Genotype
a Death/total HR (95% CI)
b P value HR (95% CI)
c P value
ANGPT1 3UTR rs1954727 WW 33/133 1(reference) 1(reference)
WV 52/192 1.25(0.80–1.93) 0.324 0.89(0.55–1.43) 0.623
VV 9/80 0.42(0.20–0.89) 0.023 0.32(0.15–0.71) 0.005
P for trend 0.084 0.008
ANGPT1 Flanking 5UTR rs9297395 WW 79/360 1(reference) 1(reference)
WV 12/32 1.74(0.95–3.19) 0.075 1.20(0.56–2.54) 0.641
VV 3/13 1.11(0.35–3.53) 0.855 0.83(0.24–2.92) 0.771
P for trend 0.232 0.900
AMOT 3UTR rs2286064 WW 81/367 1(reference) 1(reference)
WV 8/22 1.24(0.57–2.70) 0.587 2.02(0.85–4.81) 0.110
VV 5/18 1.10(0.44–2.71) 0.840 0.58(0.21–1.59) 0.290
P for trend 0.678 0.613
AMOT Coding rs2286063 WW 64/277 1(reference) 1(reference)
WV 14/52 1.29(0.72–2.31) 0.384 1.50(0.75–3.02) 0.253
VV 16/78 0.98(0.57–1.70) 0.942 1.27(0.71–2.28) 0.418
P for trend 0.879 0.375
AMOT Flanking 5UTR rs640009 WW 50/201 1(reference) 1(reference)
WV 19/85 0.95(0.56–1.62) 0.861 1.21(0.58–2.56) 0.609
VV 25/120 0.87(0.54–1.41) 0.567 0.85(0.49–1.47) 0.550
P for trend 0.570 0.951
DLL4 Flanking 5UTR rs12439845 WW 42/189 1(reference) 1(reference)
WV 40/163 0.99(0.64–1.54) 0.982 0.93(0.58–1.49) 0.760
VV 12/51 0.93(0.49–1.76) 0.820 0.60(0.28–1.29) 0.190
P for trend 0.850 0.118
ENG Flanking 5UTR rs7865146 WW 19/74 1(reference) 1(reference)
WV 44/200 0.98(0.56–1.69) 0.936 0.63(0.34–1.17) 0.146
VV 31/130 1.07(0.60–1.92) 0.819 1.09(0.55–2.19) 0.800
P for trend 0.778 0.818
Note: The significant P values (#0.05) were in bold.
aWW, homozygous wild-type genotype; WV heterozygous genotype; VV, homozygous variant genotype.
bUnivariate analysis.
cAdjusted for age, gender, smoking status, drinking status, BMI, tumor position, tumor differentiation, tumor stage and chemotherapy.
doi:10.1371/journal.pone.0034758.t002
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treatment [24]. However, these VEGF-targeting anti-angiogenesis
treatments frequently result in only transient responses in cancer
patients, primarily owing to the two modes of resistance to
angiogenesis inhibition, adaptive resistance and intrinsic non-
responsiveness [13]. Both modes of resistance can be attributed to
the inherent heterogeneity of genetically unstable tumor cells, the
presence of redundant angiogenic factors, and the recruitment of
hematopoietic cells and inflammatory cells into the tumor mass
[13]. It is conceivable that therapeutic approaches simultaneously
targeting multiple angiogenic factors, inflammatory pathways, and
metastasis processes could induce more clinically meaningful
responses [25]. The ANGPT-TIE pathway presents an attractive
opportunity for such a therapeutic intervention as it is not only
crucial for angiogenesis and vascular homeostasis in an VEGF-
independent manner, but it also provides an important link
between the angiogenesis and the inflammation pathways [25].
Human ANGPT-TIE protein family is composed of three
ligands, ANGPT1, ANGPT2 and ANGPT4, as well as two
receptors, TIE1 and TIE2. ANGPT1 is the most important
mediator of VEGF-independent pro-angiogenic signaling path-
way, which activates the downstream PI3K/AKT pathway
through the interaction with the TIE2 protein [26,27]. ANGPT2
inhibits ANGPT1 binding to the TIE2 receptor and prevents its
activation [28]. Dynamic balance and sequential expression of
ANGPTs and VEGF is required for maintaining angiogenesis
[29,30]. The up-regulation of ANGPT1 has been investigated in
many cancers, suggesting that ANGPT1 is strongly correlated with
tumor malignancy [25]. However, several studies have reported an
inhibiting effect of ANGPT1 on the pathologic vascular
expansion, indicating that ANGPT1 may also function as a tumor
suppressor in several cancers, including CRC [31,32,33,34]. These
findings were consistent with the reports of several independent
studies showing that higher ratio of ANGPT2/ANGTP1 was
associated with poor prognosis of multiple malignancies including
CRC [25]. These paradoxical findings suggest the effects of
ANGPT1 on tumor characteristics and prognosis might be cancer-
specific and also dependent on other angiogenesis-related genes.
Genetic variations in ANGPT genes may lead to altered gene
production and result in activation/inactivation of the gene. SNPs
in ANGPT1 gene have been associated with the risk of diseases
such as autoimmune diseases, juvenile idiopathic arthritis, and
portopulmonary hypertension [35,36]. However, to date, there
has been no study reporting an association of ANGPT1 SNPs with
the risk and clinical outcome of cancers. In this study, we identified
an ANGPT1 SNP, rs1954727, which may predict the overall
survival of CRC patients after surgery. This SNP is located in the
39 UTR of ANGPT1 gene. Functional SNPs in this region may
affect messenger RNA stability or microRNA binding. A
bioinformatics search of the PolymiRTS database did not identify
Table 3. Modulating effects of chemotherapy on colorectal cancer overall survival by rs1954727 genotypes.
SNP and variables
a Death/total HR (95% CI)
b P value
In all patients
No chemotherapy 22/89 1(reference)
Chemotherapy 72/319 0.44(0.26–0.75) 0.002
In patients with WW genotype of rs1954727
No chemotherapy 7/31 1(reference)
Chemotherapy 26/102 0.45(0.16–1.27) 0.132
In patients with WV genotype of rs1954727
No chemotherapy 14/43 1(reference)
Chemotherapy 38/149 0.45(0.22–0.92) 0.028
In patients with VV genotype of rs1954727
No chemotherapy 1/15 1(reference)
Chemotherapy 8/65 0.19(0.01–4.25) 0.297
Note: The significant P values (#0.05) were in bold.
aWW, homozygous wild-type genotype; WV heterozygous genotype; VV, homozygous variant genotype.
bAdjusted for age, gender, smoking status, drinking status, BMI, tumor position, tumor differentiation, tumor stage, and chemotherapy, where appropriate.
doi:10.1371/journal.pone.0034758.t003
Figure 1. Kaplan-Meier curves and log rank tests for
rs1954727.
doi:10.1371/journal.pone.0034758.g001
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region of this SNP [37]. However, a further search led to the
identification of four SNPs in the 39UTR of ANGPT1 gene that are
located within putative miRNA binding regions (data not shown).
The nearest SNP is about 600 nucleotides away from rs1954727.
Functional characterizations such as real-time PCR followed by
luciferase assay will be needed to determine whether rs1954727
has any direct physiological impact on messenger RNA expression
of ANGPT1.
In stratified analysis, we found the protective effect conferred by
rs1954727 was more prominent in patients receiving chemother-
apy (Table S1). Previous studies have reported a significantly
increased antitumor activity upon the joint use of ANGPT1
antibody and chemotherapy in treating solid tumors including
CRC [38]. These lines of evidence led us to further evaluate the
modulating effect of chemotherapy on patient survival stratified by
the genotypes of rs1954727. Consistent with the finding that the
variant genotypes of rs1954727 conferred better overall survival in
chemotherapy-treated patients, we found the improved survival
conferred by chemotherapy remained evident in patients with the
heterozygous genotype of rs1954727 (Table 4). We also noted that
in patients with the homozygous variant genotype of rs1954727,
the P value was not significant (P=0.297), although the improved
overall survival conferred by chemotherapy was much more
prominent (HR=0.19). This may be due to an unstable estimate
resulting from the small patient number in this group (only 1 death
in patients without chemotherapy, Table 3).Future studies with
larger sample size are needed to provide sufficient statistical power
to the analysis of the interactions between rs1954727 and
chemotherapy on patient survival.
There are several strengths in this study. The patients were
enrolled from Xi’an and adjacent area, a region that is highly
attractive for conducting population-based research due to the
geographical stability with low mobility rate. Also, the patients
analyzed in this study were highly homogenous, in that all patients
had adenocarcinoma and were surgically treated to remove the
primary tumors. Additionally, all chemotherapy treatments were
started within 2 months of surgery and almost 80% of the patients
received chemotherapy. The highly homogenous patient charac-
teristics and treatments, as well as low rate of patient loss to follow-
up, greatly reduced the confounding effects of the heterogeneous
therapeutics modalities in many other similar biomarker studies of
CRC prognosis. The limitations of our study include the
generalizability issue, because our study was restricted to Han
Chinese. Further evaluation is necessary to determine whether
these findings can be generalized to other ethnic groups.
Moreover, the moderate sample size limited the validity of some
stratified analyses with small sample size. We analyzed the study
power for the main effect analysis as well as the chemotherapy-
stratified analysis. Under the condition of an additive genetic
model (used in the analysis of this study) with monotonic effect, an
MAF of 43.5% for rs1954727, the only significant SNP identified
in this study, 23.0% of death rate among the total study
population, a median time to death of 15.2 months in deceased
patients and a median time of follow-up of 23.9 months in
censored patients, we have approximately 82% power to detect an
HR of 0.6 (heterozygous genotype vs. homozygous wild-type
genotype) and 0.4 (homozygous variant genotype vs. wild-type
genotype). The power is slightly higher if using a trend test. When
the analysis is restricted to the patients receiving chemotherapy,
our power is approximately 70% to detect the aforementioned
effect sizes. However, our power is limited when the analysis is
restricted to the 89 patients without chemotherapy or some other
non-significant SNPs in this study that have a low MAF, and the
results of these under-powered analyses are exploratory and should
be interpreted with caution. Nonetheless, the enrollment of this
population is still ongoing with a low rate of patient loss, which will
enable us to obtain higher statistical power for in-depth analyses in
the future.
In conclusion, our finding suggests that a genetic polymorphism
in ANGPT1 gene is associated with a significantly better overall
survival in CRC patients after surgery. Future studies with larger
populations are needed to validate this finding.
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